ACTRN12611000394943尚未招募4 期
The combination of rosuvastatin and fenofibrate and metoprolol can impede coronary atheroma plaque progression detected by multi-detector spiral computed tomography
适应症
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 入组人数
- 520
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 70 Years（—）
- 性别
- All
入选标准
- •1.no chest pain or atypical chest pain
- •2.mild to moderate coronary atheroma plaque by multidetector computed tomography (MDCT)
- •3. diameter narrowing is less than 50%
- •4. low-density lipoprotein cholesterol(LDL-C)>100mg/dl, triglyceride(TG)>150 mg/d
排除标准
- •known coronary artery disease; previous coronary revascularization; signs or symptoms suggesting ischemia and coronary revascularization needed in a short time; current lipid-lowering pharmacotherapy; known genetic form of dyslipidemia; creatinine > 1.5 mg/dL; ALT or AST>40u/L; fasting serum TG> 500 mg/dL; inability to perform MDCT; uncontrolled hypertension; decompensated heart failure (class IV); known pregnancy; combined condition decreasing life expectancy; heart rate<60 beats/min; sick sinus syndrome; atrioventricular block over 2 degree type 2
研究者
相似试验
已完成
3 期
Phase III Study of Rosuvastatin and Fenofibrate Versus Rosuvastatin in Mixed DyslipidemiaMixed DyslipidemiasNCT02262143IlDong Pharmaceutical Co Ltd362
已完成
4 期
Tolerability and Efficacy of Rosuvastatin - Fenofibrate Combine Therapy in Korean Patients With Combined HyperlipidemiaHyperlipidemiaNCT01414803Yonsei University180
招募中
3 期
Effect of Pemafibrate and Rosuvastatin or Rosuvastatin Alone on Lipid Core Plaques in Coronary Artery Disease Evaluated by Near-infrared Spectroscopy Intravascular UltrasoundJPRN-jRCT1051190122Toh Ryuji46
招募中
4 期
Efficacy and safety of rosuvastatin combined with Shouhui Tongbian capsule in the treatment of dyslipidemia: a prospective, single-center, open, randomized controlled studyDyslipidemiaITMCTR2100004388Beijing Friendship Hospital Affiliated to Capital Medical University
进行中（未招募）
1 期
Fixed-dose combination of rosuvastatin and valsartan for dual target achievement in patients with hypertension and hyperlipidaemia (UNIFY)Patients with mild to moderate essential arterial hypertension AND primary hypercholesterolemia or mixed dyslipidaemia (LDL-c < 4.9 mmol/L or <189.5 mg/dl) with moderate, high or very high risk for cardiovascular event.MedDRA version: 20.0 Level: PT Classification code 10062060 Term: Hyperlipidaemia System Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 20.0 Level: PT Classification code 10015488 Term: Essential hypertension System Organ Class: 10047065 - Vascular disordersEUCTR2017-003672-31-HUKRKA, d.d., Novo mesto280